Yazdanpanah, Y., Khuong-Josses, M., Hocqueloux, L., Pialoux, G., Durant, J., Wynne, B., . . . Min, S. (2014). 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE trial. BMC Infect Dis.
Dyfyniad Arddull ChicagoYazdanpanah, Y., et al. "48 Week Bone Marker Changes With Dolutegravir (DTG) Plus Abacavir/Lamivudine (ABC/3TC) Vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial." BMC Infect Dis 2014.
Dyfyniad MLAYazdanpanah, Y., et al. "48 Week Bone Marker Changes With Dolutegravir (DTG) Plus Abacavir/Lamivudine (ABC/3TC) Vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial." BMC Infect Dis 2014.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.